Evidence map›Paper›PMID 33776370›Full record

ReviewWorld journal of gastroenterology2021

How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician.

Júlio Maria Fonseca Chebli, Natália Sousa Freitas Queiroz, Adérson Omar Mourão Cintra Damião, Liliana Andrade Chebli, Márcia Henriques de Magalhães Costa, Rogério Serafim Parra

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study.Journal of the Formosan Medical Association = Taiwan yi zhi · 2023
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Increased Hospitalization for IBD Patients Seen in the ER During the COVID-19 Pandemic.Journal of the Canadian Association of Gastroenterology · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Júlio Maria Fonseca ChebliDivision of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, Federal University of Juiz de Fora, Juiz de Fora 36036-900, MG, Brazil.
Natália Sousa Freitas QueirozDepartment of Gastroenterology, University of São Paulo School of Medicine, São Paulo 05403-000, SP, Brazil.
Adérson Omar Mourão Cintra DamiãoDepartment of Gastroenterology, University of São Paulo School of Medicine, São Paulo 05403-000, SP, Brazil.
Liliana Andrade ChebliDivision of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, Federal University of Juiz de Fora, Juiz de Fora 36036-900, MG, Brazil.
Márcia Henriques de Magalhães CostaDepartment of Clinical Medicine, Fluminense Federal University, Rio de Janeiro 24210-200, RJ, Brazil.
Rogério Serafim ParraDepartment of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14048-900, SP, Brazil. rsparra@hcrp.usp.br.
Universidade de São Paulo · BRUniversidade Federal de Juiz de Fora · BRUniversidade de Ribeirão Preto · BRUniversidade Federal Fluminense · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Managing inflammatory bowel disease (IBD) during the coronavirus disease 2019 (COVID-19) pandemic has been a challenge faced by clinicians and their patients, especially concerning whether to proceed with biologics and immunosuppressive agents in the background of a global outbreak of a highly contagious new coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2). The knowledge about the impact of this virus on patients with IBD, although it is still scarce, is rapidly evolving. In particular, concerns surrounding medications' impact for IBD on the risk of acquiring SARS-CoV-2 infection or developing COVID-19, and potentially exacerbate viral replication and the COVID-19 course, are a current thinking of both practicing clinicians and providers caring for patients with IBD. Managing patients with IBD infected with SARS-CoV-2 depends on both the clinical activity of the IBD and the occasional development and severity of COVID-19. In this review, we summarize the current data regarding gastrointestinal involvement by SARS-CoV-2 and pharmacologic and surgical management for IBD concerning this infection, and the COVID-19 impact on both the patient's psychological functioning and endoscopy services, and we concisely summarize the telemedicine roles during the COVID-19 pandemic.

Indexed as

TelemedicineAmbulatory CareBiological ProductsCarrier StateCOVID-19DeprescriptionsDisease ManagementEndoscopy, GastrointestinalGlucocorticoidsHospitalizationHumansImmunologic FactorsImmunosuppressive AgentsInflammatory Bowel DiseasesPractice Guidelines as TopicRisk FactorsBiological ProductsGlucocorticoidsImmunologic FactorsImmunosuppressive AgentsBiological therapyColitis ulcerativeCOVID-19Crohn diseaseInflammatory bowel diseaseSARS-CoV-2

Identifiers

PMID33776370
PMCPMC7985732
OpenAlexW3138696544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.